# A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

> **NCT03816176** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Invasive Mucormycosis
- Invasive Aspergillosis

## Interventions

- **DRUG:** Isavuconazonium sulfate
- **DRUG:** Isavuconazonium sulfate

## Key facts

- **NCT ID:** NCT03816176
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-22
- **Primary completion:** 2022-12-14
- **Final completion:** 2022-12-14
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03816176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03816176, "A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03816176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*